“Enlitic’s rapid growth, including our successful fundraising, points to the enthusiasm and confidence we have elicited in the marketplace with the development of our comprehensive AI software platform and our highly efficient business model,” said Kevin Lyman, Enlitic’s Chief Executive Officer. “We look forward to formally debuting our platform at RSNA 2019 in December and to its market deployment in 2020.”
Alex Waislitz, Founder and Chairman of Thorney Investment Group said, “The global healthcare industry is experiencing the dawn of a new age with artificial intelligence and we are excited to be at its forefront with our investment in Enlitic and the company’s game changing AI-powered software platform.”
Commenting on the appointment of Lawrence Gozlan to Enlitic’s board of directors, Michael Sistenich, Enlitic’s Board Chairman said, “Lawrence joins us with one of the most extensive backgrounds in the biotechnology and healthcare investment communities. I am certain that his expertise and keen eye to the future of global healthcare will add tremendous value to our board.”
About Enlitic
Named one of the world’s “50 Smartest Companies” by MIT Technology Review, Enlitic is a pioneer in medical deep learning, building a best-in-class platform that bridges human and artificial intelligence to save time, money, and ultimately, lives. The company’s team of practicing radiologists, data scientists, and software engineers analyze a vast stream of healthcare data –– including millions of clinical cases from cross-sector healthcare partners –– to improve diagnostic accuracy, speed, and patient outcomes, as well as to accelerate pharmaceutical research and drug trials. Enlitic is based in San Francisco and has offices in New York and Sydney, Australia.
Back to HCB News
